Sugi Predict

Sugi Predict / Compounds / SCHEMBL2524800

SCHEMBL2524800

SCHEMBL2524800

O=C1CCc2ccc(OCc3ccccc3)cc21

nearest known ligand 0.84

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 13/20 0.84
▸ MAOA P21397 12/20 0.84
▸ NPC1 O15118 1/20 0.59
▸ ALDH1A1 P00352 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ NFKB1 P19838 1/20 0.59
▸ GRM5 P41594 1/20 0.59
▸ RAB9A P51151 1/20 0.59
▸ NFKB2 Q00653 1/20 0.59
▸ RELA Q04206 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59
▸ TOP1 P11387 1/20 0.57
▸ HRH3 Q9Y5N1 3/20 0.54
▸ GSTP1 P09211 1/20 0.53
▸ CA2 P00918 1/20 0.51
▸ CA5A P35218 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353268 1.00 MAOB (0.84) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL30067289 0.91 MAOB (1.00) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL3501723 0.91 MAOB (1.00) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL7215662 0.91 MAOB (0.94) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL327001 0.88 MAOB (0.84) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL2314862 0.88 MAOB (0.74) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL27895 0.85 MAOB (0.67) MAOBMAOANPC1RAB9AHRH3
SCHEMBL7218099 0.85 MAOB (0.82) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL3759785 0.81 MAOB (0.74) MAOBMAOANPC1ALDH1A1HPGD
SCHEMBL17585141 0.81 MAOB (0.65) MAOBMAOANPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497377-B2 Tricyclic spiro compound ONO PHARMACEUTICAL CO., LTD. (JP) 2025-12-16 — — US disclosed
CN-111039916-B Tricyclic spiro compounds 小野药品工业株式会社 2023-04-28 — — CN disclosed
US-20220048881-A1 TRICYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2022-02-17 — — US disclosed
US-11192876-B2 Tricyclic spiro compound ONO PHARMACEUTICAL CO., LTD. (JP) 2021-12-07 — — US disclosed
EP-3482760-B1 COMBINATION COMPRISING EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR ONO PHARMACEUTICAL CO (JP) 2021-11-10 — — EP disclosed
US-11065226-B2 Combination comprising EP4 antagonist and immune checkpoint inhibitor ONO PHARMACEUTICAL CO., LTD. (JP) 2021-07-20 — — US disclosed
CN-109475520-B Combinations comprising an EP4 antagonist and an immune checkpoint inhibitor 小野药品工业株式会社 2021-05-14 — — CN disclosed
EP-3778562-A1 TRICYCLIC SPIRO COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2021-02-17 — — EP disclosed
CN-111039916-A Tricyclic spiro compounds 小野药品工业株式会社 2020-04-21 — — CN disclosed
US-20200102284-A1 TRICYCLIC SPIRO COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2020-04-02 — — US disclosed
US-20100298367-A1 Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders AMGEN INC. 2010-11-25 — — US disclosed
US-20100105725-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2010-04-29 — — US disclosed
US-20100105725-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2010-04-29 — — US disclosed
US-20100105725-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2010-04-29 — — US disclosed
WO-2009111056-A1 CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2009-09-11 — — WO disclosed
WO-2009111056-A1 CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2009-09-11 — — WO disclosed
EP-2079467-A2 ANTIDIABETIC BICYCLIC COMPOUNDS Merck & Co., Inc. (US) 2009-07-22 — — EP disclosed
WO-2008054675-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2008-05-08 — — WO disclosed
WO-2008054675-A2 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK & CO., INC. (US) 2008-05-08 — — WO disclosed
US-5504104-A TREATING INFECTIONS OR DISEASES CAUSED BY RETROVIRUSES, SUCH AS HIV AND AIDS WARNER-LAMBERT COMPANY (US) 1996-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105725-A1 ANTIDIABETIC BICYCLIC COMPOUNDS GPR119, FFAR2, GPR65 MAOB 3566/4885MAOA 3472/4885NPC1 1546/4885
US-20100298367-A1 Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders PC, GOT2, CS MAOB 926/4885MAOA 1014/4885NPC1 707/4885
US-11192876-B2 Tricyclic spiro compound PTGER4, PTGER1, PTGER3 MAOB 2126/4885MAOA 2145/4885NPC1 577/4885
US-20200102284-A1 TRICYCLIC SPIRO COMPOUND PTGER4, PTGER1, PTGER3 MAOB 2126/4885MAOA 2145/4885NPC1 577/4885
US-20220048881-A1 TRICYCLIC SPIRO COMPOUND PTGER4, PTGER1, PTGER3 MAOB 2126/4885MAOA 2145/4885NPC1 577/4885
US-11065226-B2 Combination comprising EP4 antagonist and immune checkpoint inhibitor CD274, PTGER4, PTGER1 MAOB 3297/4885MAOA 3117/4885NPC1 2976/4885
US-12497377-B2 Tricyclic spiro compound PTGER4, PTGER1, PTGER3 MAOB 2126/4885MAOA 2145/4885NPC1 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.